Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model

Abstract

Achieving WHO elimination targets with treatment scale-up is likely to be cost-effective, based on Australian HCV burden and demographics. Reducing incidence should be a priority to achieve both WHO elimination goals in the long-term.